INTRODUCTION
Farnesyltransferase inhibitors (FTIs) have undergone extensive clinical testing in various hematological malignancies. [1] [2] [3] A recent multi-institution phase II study demonstrated that the orally bioavailable nonpeptidomimetic FTI tipifarnib 4 induces partial and complete remissions, including highly durable remissions, in up to 50% of patients with relapsed Hodgkin's disease and peripheral T cell lymphomas. 5 Phase II and phase III studies have also demonstrated responses in 11 to 23% in elderly patients with previously untreated poor risk AML. 6, 7 Moreover, a recent multicenter phase II trial has shown that tipifarnib improves early survival when administered as maintenance therapy in remission. 8 Accordingly, there is considerable interest in better understanding the mechanism of cytotoxicity of FTIs.
Previous studies have suggested that many chemotherapeutic agents induce apoptosis through the mitochondrial or intrinsic pathway. 9, 10 This pathway is regulated by interactions between pro-and anti-apoptotic members of the Bcl-2 family, which modulate mitochondrial outer membrane integrity. [11] [12] [13] In particular, Bax and Bak are responsible for mitochondrial outer membrane permeabilization, leading to cytochrome c release, caspase 9 activation and subsequent apoptotic events. [12] [13] [14] Bax and Bak are held in check by binding to antiapoptotic proteins such as Bcl-2, Bcl-x L and Mcl-1. These interactions are in turn regulated by a variety of posttranslational modifications as well as the expression and activation of BH3-only family members such as Bim, Bid, Puma, and Noxa, which neutralize antiapoptotic Bcl-2 family members and/or directly activate Bax and Bak. [11] [12] [13] 15 In a recent study, we demonstrated that tipifarnib-induced killing of malignant lymphoid cells results from diminished signaling through the Raf/MEK/ERK pathway leading to upregulation of Bim, its trafficking to mitochondria, and subsequent cytochrome c release. 16 The observation that downregulation RasGRP1, a Ras guanine nucleotide exchange factor, 17 protects malignant lymphoid lines from tipifarnib-induced killing implicated H-Ras in the cytotoxic effects of FTIs in these cells. 16 Although only a small number of samples were available for analysis, clinical responses also appeared to occur preferentially in lymphomas with high RasGRP1 and low Bcl-2. 5 Whether inhibition of the Ras/Raf/MEK/ERK pathway leading to Bim upregulation is also responsible for the sporadic activity of tipifarnib in AML has been unclear. Earlier studies failed to demonstrate a correlation between inhibition of ERK phosphorylation during tipifarnib treatment and response of AMLs to therapy, 6 suggesting that AML response might differ from that in lymphoid cells. Although gene expression studies initially identified a correlation between
RasGRP1 mRNA and response of AML to tipifarnib, 18 subsequent selection of AML patients based on RasGRP1 expression failed to enrich for tipifarnib responders, 19 again arguing that human AML might be responding differently from lymphoma.
Investigations have shown that Rheb, a small GTPase involved in activating the serine/threonine kinase mammalian target of rapamycin (mTOR), also requires farnesylation for proper membrane association. 20, 21 As a result, lymphomas induced by Rheb overexpression are sensitive to FTI treatment. 22 In accord with these studies, our prior studies have shown that tipifarnib inhibits phosphorylation of p70 S6 kinase and its substrate ribosomal protein S6 in clinical AML samples without affecting phosphorylation of Akt substrates, 23 pointing to Rheb as a potentially important FTI target in AML as well. How Rheb inhibition leads to antineoplastic effects, however, has remained uncertain.
Building on these earlier observations, the present studies were designed to explore the mechanism by which tipifarnib induces apoptosis in AML cells, focusing on Rheb and subsequent changes in Bcl-2 family members. Results of these studies identified a pathway involving Puma and Bax stabilization in tipifarnib-induced killing of human myeloid cells, thereby demonstrating that the mechanism of cytotoxicity in AML differs markedly from that in malignant human lymphoid cells.
METHODS

Materials.
Tipifarnib was provided by David End (Johnson & Johnson, New Brunswick, NJ).
The broad spectrum caspase inhibitor Q-VD-OPh 24 was from SM Biochemicals (Anaheim, CA).
Additional reagents and antibodies are described in the on-line Supplemental Methods.
Cell culture. AML cell lines were authenticated and passaged as described in the on-line Supplemental Methods. To generate resistant U937 cells, parental cells were exposed continuously to increasing tipifarnib concentrations over a 6-month period. Individual clones were generated by limiting dilution at 1 cell/10 wells in the continuous presence of 800 nM tipifarnib. U937 cells stably expressing Puma or Bax shRNA 25 were generated by lentiviral transduction 26 followed 48 h later by addition of 2 μg/ml puromycin to select stable transductants, which were then cloned by limiting dilution.
Clinical samples. After Institutional Review Board approval and patient informed consent, bone marrow aspirates were harvested prior to therapy and, if patients consented, again prior to drug ingestion on day 8 of treatment with twice daily tipifarnib, which was administrated as part of a phase II trial of single-agent tipifarnib 27 or a phase II trial of the tipifarnib/etoposide combination 28 in AML. Marrow mononuclear cells were prepared on ficoll-Hypaque gradients, washed with serum-free RPMI 1640 medium, and prepared for electrophoresis.
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Immunoprecipitation and immunoblotting. Immunoprecipitation of active Bax was performed using methods previously described for the detection of active Bak, 16 but substituting the 6A7
anti-active Bax antibody. Blotting of immunoprecipitates was performed as described. 16 Whole cell lysates were prepared from cell lines or clinical samples as described previously. 29 Aliquots were resuspended in SDS sample buffer at 5 mg protein/ml as assayed by the bicinchoninic acid method, separated by SDS-PAGE, transferred to nitrocellulose membranes, and probed with various antibodies.
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MTS assay, detection of cell cycle distribution and apoptosis. MTS assays 16 as well as staining with propidium iodide followed by flow cytometry to determine cell cycle distribution and DNA fragmentation, annexin V staining and Hoechst staining for apoptotic nuclear changes were performed as described.
23,31,32
Microarray analyses and connectivity map assessment. Using methods described in the online Supplemental Methods, RNA was isolated from parental cells treated for 48 h with 0.1% DMSO or tipifarnib (800 nM, U937 and ML-1; 3200 nM, HL-60) or resistant cells growing in the same tipifarnib concentrations and hybridized to Affymetrix U133A 2.0 microarrays. After probes were corrected for GC content 33 followed by nonlinear normalization 34 applied to the perfect match data from all chips together, probes were then summarized to the probeset level via RMA. 35 Empirical Bayes linear models 36 were then used to test the hypothesis of differential expression between samples treated with diluent vs. tipifarnib. Probes with a with a metric based on the Kolmogorov-Smimov statistic and combined to produce a "connectivity score" as described.
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RESULTS
Antiproliferative effect of tipifarnib in AML cell lines. To identify a model system for studying tipifarnib action in AML, the human AML cell lines U937, ML-1, and HL-60 were exposed to increasing but therapeutically achievable tipifarnib concentrations. 38 Compared to untreated cells, the tipifarnib treated cells continued proliferating for several days and then slowed ( Figure 1A -C, left panels). Analysis of cell number on day 6 revealed that 25-100 nM tipifarnib inhibited proliferation by 50% ( Figure 1A cells. This analysis demonstrated that tipifarnib decreased the mobility of Rheb (Figure 2A ), consistent with the inhibition of farnesylation and downstream farnesylation-dependent processing. 21 Decreased phosphorylation of mTOR Ser 2448 (a marker of active mTOR in mTORC1) 39 , p70S6 kinase at Thr 389 and ribosomal S6 protein at Ser 235,236 was also observed over the same tipifarnib concentration range ( Figure 3A ). In contrast, there was no decrease in phosphorylation of the Akt substrates TSC2, PRAS40 or GSK3β (Supplementary online Figure   S3 ). This is consistent with inhibition of signaling at the level of Rheb.
To further assess the potential importance of these changes, cells were transfected with a mutant Rheb construct that becomes membrane associated after geranylgeranylation (Rheb M184L) rather than farnesylation. 21 This construct diminished tipifarnib-induced changes in ribosomal S6 phosphorylation ( Figure 3B ), tipifarnib-induced effects on proliferation (not shown) and tipifarnib-induced killing ( Figure 3C ), suggesting a critical role for Rheb inhibition in all of these processes.
In an initial attempt to tie these effects to tipifarnib-induced cell cycle arrest and/or apoptosis, the three AML cell lines were treated with tipifarnib for 48 h and harvested for preparation of RNA, which was hybridized to Affymetrix U133 2.0 arrays. Comparison of diluent-and tipifarnib-treated cells revealed statistically significant (p<0.05) two-fold or greater changes in 34, 27, and 759 transcripts in U937, ML-1, and HL-60 cells, respectively (Supplementary online Figure S4A ).
In view of our results indicating that tipifarnib diminishes mTOR-mediated phosphorylation of p70S6 kinase and its substrate S6 ( Figure 3A ), we asked whether the gene expression changes resembled the pattern observed after treatment with sirolimus (rapamycin) or any other agent.
Comparison to publicly available Connectivity Maps ( Figure 6C ) and an increase in Akt-mediated inhibitory phosphorylation of the Rheb inhibitor TSC2 (data not shown). In addition, increased expression of R-Ras2, a small G-protein previously implicated in FTI resistance in fibroblasts, 40 was also observed at the protein level without any alteration in R-Ras2 message ( Figure 6D ), suggesting a change in R-Ras2 translation or stability. Similar results were observed in multiple clones (Supplementary online Figure S5A ), suggesting that the resistance might be multifactorial.
In contrast to parental cells, where prolonged tipifarnib treatment upregulated Bax Previous studies have identified a number of potential targets of FTIs, including members of the Ras, Rho and Rheb families. 41, 42 Which of these are important for FTI-mediated killing in various cell types has not been fully resolved. In fibroblasts, for example, effects on H-Ras appear to play a critical role in FTI-induced killing. 43 On the other hand, the importance of these findings for AML has never been established. 38 In the AML cell lines treated in this study, we observed inhibition of Rheb prenylation and mTOR phosphorylation on Ser 2448 as well as diminished phosphorylation of p70S6 kinase and ribosomal S6 without any change in phosphorylation of the Rheb regulator TSC2 or other Akt substrates at early timepoints ( Figure 3A ; Figure S3 ; Figure 6C ; Figure 7D ), consistent with Rheb inhibition. To our knowledge this represents the first demonstration that prenylation of endogenous Rheb (as opposed to tagged overexpressed Rheb) is inhibited by FTI treatment. The ability of Rheb M184L to protect the cells from tipifarnib ( Figure 3C ) emphasizes the potential importance of Rheb as a farnesylation target in this cell type.
Our further studies demonstrate that tipifarnib upregulates Bax in multiple AML cell lines ( Figures 4A and 7) , a finding consistent with an earlier report that tipifarnib induces Bax upregulation and killing in myeloma cell lines. 44 Several additional observations point to the critical importance of this event. First, Bax downregulation protects U937 cells from the cytotoxic effects of tipifarnib ( Figure 4D ). Second, the HL-60 cell line, which fails to upregulate Bax, fails to undergo tipifarnib-induced apoptosis ( Figure 7B , E). Importantly, signaling downstream of mTOR and proliferation are inhibited in this cell line ( Figure 1 and Figure 7) despite the absence of apoptosis, indicating that the block to tipifarnib-induced apoptosis likely occurs somewhere between mTOR inhibition and Bax stabilization. Third, signaling changes that result from selection for tipifarnib resistance have reversed the tipifarnib-induced Bax upregulation ( Figure 6 ). Collectively, these results provide the first evidence that Bax upregulation plays a critical role in FTI-induced killing in AML cell lines and highlight the potential importance of studying this process further.
Bim, tBid, and Puma are currently thought to be direct activators of Bax. 45 Our studies demonstrated that tipifarnib also upregulates Puma in AML cell lines ( Figure 4A ; Figure 7C ).
Because U937 and HL-60 cells lack p53, this Puma upregulation must be p53-independent.
Importantly, Puma shRNA inhibits tipifarnib-induced apoptosis in U937 cells ( Figure 4D Interestingly, the Bax and Puma upregulation observed after tipifarnib treatment did not result from changes in Bax or Puma mRNA ( Figure 5A-B) . Instead, both of these changes reflected increased protein half-life ( Figure 5C ). Although it is fashionable to examine druginduced changes in mRNA profiles, the present demonstration that critical changes in Bcl-2 family members occurred without any change in message (cf. Figure 3 and Figure 5 ) serves as a reminder that signal transduction modulators can have lethal effects on target cells independent of any change in mRNA expression.
As this work was being initiated, Raponi and coworkers reported that high levels of mRNA encoding the Ras guanine nucleotide exchange factor RasGRP1 were associated with a higher probability of AML response to tipifarnib. 18 While the authors speculated that high RasGRP1 might reflect activation of (and dependence on) the Ras pathway, mechanistic studies linking
RasGRP1 to the response of AML cells were not reported. Earlier studies had shown that
RasGRP1 is expressed at particularly high levels in lymphocytes 17, [47] [48] [49] but is absent from myeloid cells. 50 Consistent with these results, we have observed that RasGRP1 protein (Figure 2) is below the limit of detection in multiple AML lines. Instead, the present study demonstrates that tipifarnib can inhibit proliferation and induce apoptosis in AML cells with markedly diminished or absent RasGRP1, consistent with recent observations that RasGRP1 might not always enrich for AML that is tipifarnib responsive. 19 In the present study, tipifarnib sensitivity in AML cells depends more strongly on the ability to posttranslationally upregulate Bax.
Finally, when combined with our simultaneously performed studies of tipifarnib action in malignant lymphoid cells, 16 the present results also suggest that the mechanism of tipifarnibinduced killing depends upon the cellular context. In particular, the critical farnesylation target seems to vary from cell type to cell type. In malignant lymphoid cells, our studies point to the importance of FTI-induced inhibition of mitogen-activated protein kinase signaling downstream of Ras, leading to Bim upregulation and Bim-dependent killing. 16 In contrast, we have not observed inhibition of Akt phosphorylation or ERK phosphorylation at 24-48 hours in the AML cell lines examined here (e.g., Figure 6C and Figure 7D ), nor have we observed Bim upregulation ( Figures 4A and 7E) , arguing that AML cell killing might occur by a different mechanism. Indeed, the present results suggest that tipifarnib inhibits Rheb-mediated signaling in AML cells ( Figure 3A and Figure 7D ), leading to stabilization of Bax and Puma (Figures 4A, 4C and 7C) followed by induction of apoptosis.
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The authors have no conflicts of interest. for the corresponding mRNA sample. 28 NA, not assayed due to lack of RNA sample. 27 (G) were subjected to SDS-PAGE followed by immunoblotting for the indicated antigens. Number below panel in F indicates RasGRP1:aprataxin ratio previously reported for the corresponding mRNA sample. 28 NA, not assayed due to lack of RNA sample.
Whole cell lysates were prepared from cell lines as described previously. 29 In brief, cells were washed in serum-free RPMI-HEPES and solubilized in 6 M guanidine hydrochloride containing 250 mM Tris-HCl (pH 8.5 at 21!C), 10 mM EDTA, 1% (v/v) ß-mercaptoethanol, and 1 mM #-phenylmethylsulfonyl fluoride (freshly added from a 100 mM stock in anhydrous isopropanol). Following reaction with iodoacetamide, cell lysates were dialyzed sequentially into 4 M urea followed by 0.1% (v/v) SDS and lyophilized. 29 Aliquots were resuspended in SDS sample buffer at 5 mg protein/ml (assayed by the bicinchoninic acid method), 53 separated by SDS-PAGE, transferred to nitrocellulose membranes, and probed with various antibodies.
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MTS assay. Parental or tipifarnib-resistant cells were sedimented at 100 x g for 5 min, washed once in serum-free medium and resuspended in medium A. Aliquots containing ~2 x 10 4 cells in 120 µl medium B were incubated at 37º C with varying concentrations of tipifarnib for 6 d. After reaction with MTS and phenazine methosulfate as instructed by the supplier, plates were incubated for 2-6 h to obtain an absorbance of 0.5-1.0 at 490 nm in control samples.
RNA isolation and microarray. RNA was isolated in on three separate days from 20 x 10 6 cells treated for 48 h with 0.1% DMSO or tipifarnib (800 nM, U937 and ML-1; 3200 nM, HL-60) or resistant cells growing in the same tipifarnib concentration using the Qiagen RNeasy kit. After analysis using an Agilent BioAnalyzer 2100 to confirm RNA quality, RNA was reverse transcribed, labeled and hybridized to Affymetrix U133A 2.0 microarrays using standard techniques.
Microarray analyses and Connectivity Map assessment. Analyses were performed on the log base 2 scale. The probes were then corrected for GC content 33 followed by nonlinear normalization 34 applied to the perfect match data from all chips together, since the majority of genes were expected to be similarly expressed across all samples. Probes were then summarized to the probeset level via RMA. 35 Empirical Bayes linear models 36 were then used to test the hypothesis of differential expression between samples treated with diluent vs. tipifarnib. Probes with a fold change in the tipifarnib treated cells of at least 2.0 and p value <0.05 were used in further analysis at the Broad Institute's Connectivity Map website (www.broadinstitute.org/cmap/newQuery). The version used (build02) contained 7000 genomewide expression profiles derived from treating various human cell lines with 1309 bioactive small molecules. Enrichment of the induced and repressed genes of a signature within each Connectivity Map treatment profile was estimated with a metric based on the KolmogorovSmimov statistic and combined to produce a "connectivity score" as previously described.
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Quantitative RT-PCR. After total RNA was isolated from control or tipifarnib-treated U937 cells, quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) was performed in triplicate using 100 ng RNA and TaqMan One-Step RT-PCR Master Mix (Applied Biosystems, Carlsbad, CA) per the supplier's instructions. Using Bax (Hs00180269_m1) and Puma (Hs00248075_m1) probe sets, PCR was performed on a ABI Prism 7900HT Real_Time System using a program consisting of 48 °C for 30 min, 95 °C for 10 min, then 40 cycles of 95 °C for 15 sec and 60 °C for 1 min. Data analysis was performed using the following equations: $C t =C t (sample)-C t (endogenous control); $$C t =$C t (sample)-$C t (untreated); and Fold Change = 2-$$C t . Figure S1 . Tipifarnib inhibits proliferation in Jurkat T-cell ALL cells. Aliquots containing 1 x 10 5 Jurkat cells/ml were treated with the indicated concentrations of tipifarnib or diluent continuously, with cells being counted and diluted into fresh medium with drug every 2 days. Graph at left indicates cumulative cell number/ml after taking into account dilution. Graph on right shows cell number on day 6 relative to diluent-treated controls. Figure S2 . Induction of apoptosis in U937 cells. A, U937 cells were fed with fresh medium containing 400 nM tipifarnib every two days to yield the indicated exposure time, then stained with propidium iodide and subjected to flow microfluorimetry. B, results of assays shown in panel A and additional time points. C-F, after treatment with diluent or 800 nM tipifarnib for 6 days, U937 cells were stained with APC-annexin V and examined by flow microfluorimetry (C,D) or fixed with 3:1 methanol:acetic acid, stained with Hoechst 33258 and examined by fluorescence microscopy (E, F). Circle in E, typical group of apoptotic fragments counted as one apoptotic cell. Error bars in D and F, mean ± SD of 3 independent experiments. Figure S3 . Lack of detectable effect of tipifarnib on signaling upstream and immediately downstream of Akt. After U937 cells were treated for 24 h with the indicated tipifarnib concentration, whole cell lysates (the same samples shown in Figure 3 ) were subjected to immunoblotting with antibodies that recognize the indicated antigens. GAPDH served as a loading control. Grey arrow indicates farnesylated HDJ-2 and black arrow indicates unfarnesylated antigen. Figure S4 . Tipifarnib-induced mRNA changes in AML cell lines are similar to other PI3 kinase/mTOR inhibitors. A, after U937, HL-60 or ML-1 were treated for 48 h with diluent or tipifarnib at 800, 1600, or 800 nM, respectively, cDNA was prepared and hybridized to Affymetrix 133 2.0 microarrays as described in the Methods. Numbers in each circle indicate the number of mRNAs for which changes were statistically significance (p <0.05) and more than 2-fold in amount between control and tipifarnib-treated cells. B, correlation coefficient between mRNA changes induced by tipifarnib (panel A) in the present study and mRNA changes described at the Broad Institute Connectivity website in multiple experiments with each drug. Figure S5 . Further characterization of tipifarnib-resistant U937 cells. A, immunoblot of whole cell lysates from parental U937, bulk culture of U937 selected for growth in 800 nM tipifarnib, and three separate tipifarnib-resistant clones isolated by limiting dilution. B, tipifarnibresistant U937 cells growing in 800 nM tipifarnib (lanes 1-4) or parental cells without drug (lanes 5-8) were treated with 30 µM cycloheximide for 0-48 h in the continued presence (lanes 1-4) or absence (lanes 5-8) of tipifarnib, then subjected to SDS-PAGE followed by immunoblotting with antibodies that recognize the indicated antigens. GAPDH served as loading a loading control.
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